In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acclarent: Can Balloons Open Sinuses and the ENT Device Market?

Executive Summary

Acclarent is developing interventional technology for the sinuses, targeting a clinical specialty unfamiliar with these techniques, in the hope of expanding an under-served device area. But will ENT surgeons welcome the change?

You may also be interested in...



Intersect Follows Leaders In ENT

Following the lead of ENT start-ups like Acclarent and Entellus Medical, Intersect ENT Inc. is introducing a line of stent like implants capable of performing the same role drug-eluting stents played in interventional cardiology. Intersect’s implants provide moderate structural support to tissue that has been cut or dilated through FESS or balloon sinuplasty. But the principal function of the implant isn’t propping open nasal passageways but rather delivering drugs. A trio of clinical studies conducted by the company has found the released steroids produced statistically significant reductions in inflammation, polyp formation, and postoperative adhesions.

Entellus: Helping The Interventional Revolution Balloon In Sinus Therapy

The second company in the US looking to replace certain sinus surgeries with interventional procedures, Entellus is looking to further advance this technology by moving treatment from the OR to the doctor's office.

Entellus: Helping The Interventional Revolution Balloon In Sinus Therapy

The second company in the US looking to replace certain sinus surgeries with interventional procedures, Entellus is looking to further advance this technology by moving treatment from the OR to the doctor's office.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel